Stephen Harvey
Director/Miembro de la Junta en CastleVax, Inc. .
Perfil
Stephen Harvey is currently a Director at CastleVax, Inc. He previously worked as a Senior Vice President-Finance at The Mount Sinai Hospital.
Cargos activos de Stephen Harvey
| Empresas | Cargo | Inicio |
|---|---|---|
CastleVax, Inc.
 CastleVax, Inc. BiotechnologyHealth Technology CastleVax, Inc. is an American vaccine platform company based on technology developed at the Icahn School of Medicine at Mount Sinai, headquartered in an undisclosed location. The private company's platform uses a disease virus to induce the human immune system to produce neutralizing antibodies targeted at a range of emerging and pandemic viruses, including SARS-CoV-2. The technology was developed in response to the growing need for vaccine independence and pandemic response preparedness. CastleVax's leading candidate, NDV-HXP-S, is currently being tested in clinical trials in multiple countries around the world. The company was founded by Florian Krammer, Peter Palese, Adolfo García-Sastre. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Stephen Harvey.
| Empresas | Cargo | Fin |
|---|---|---|
The Mount Sinai Hospital
 The Mount Sinai Hospital Hospital/Nursing ManagementHealth Services The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY. | Director Financiero/CFO | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
The Mount Sinai Hospital
The Mount Sinai Hospital Hospital/Nursing ManagementHealth Services The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY. | Health Services |
CastleVax, Inc.
CastleVax, Inc. BiotechnologyHealth Technology CastleVax, Inc. is an American vaccine platform company based on technology developed at the Icahn School of Medicine at Mount Sinai, headquartered in an undisclosed location. The private company's platform uses a disease virus to induce the human immune system to produce neutralizing antibodies targeted at a range of emerging and pandemic viruses, including SARS-CoV-2. The technology was developed in response to the growing need for vaccine independence and pandemic response preparedness. CastleVax's leading candidate, NDV-HXP-S, is currently being tested in clinical trials in multiple countries around the world. The company was founded by Florian Krammer, Peter Palese, Adolfo García-Sastre. | Health Technology |
- Bolsa de valores
- Insiders
- Stephen Harvey
